Skip to content

Study · Randomized controlled trial · n = 17 · 2019

9 results

Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.

Hövelmann U, Olsen MB, Mouritzen U, Lamers D, Kronshage B, Heise T

Diabetes, obesity & metabolism28 Nov 2018Cited by 21 (Europe PMC)

PMID30350477 (opens in a new tab)PMCIDPMC6587565 (opens in a new tab)DOI10.1111/dom.13562 (opens in a new tab)PepBankPUB-30350477
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In type 1 diabetes, dasiglucagon led to dose-dependent mean glucose increases of 2.2 to 4.4 mmol/L (39-80 mg/dL) at 30 minutes post-dosing from euglycaemia.

    In plain wordsDasiglucagon increased glucose from normal starting levels in adults with type 1 diabetes.

    Peptide
    Dasiglucagon
    Outcome
    IncreaseGlucose increase from euglycemia
    Study

    n = 17

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.03-0.6 mg · subcutaneousAs given in this study (human).

    Measurements

    Mean PG increase 30 min post-dosing, euglycaemia
    2.2 to 4.4 mmol/L
    dasiglucagon, range across doses tested
    Mean PG increase 30 min post-dosing, euglycaemia
    39 to 80 mg/dL
    dasiglucagon, range across doses tested

    Source sentences

    Summary
    Dasiglucagon led to a dose-dependent and rapid increase in PG levels across all doses tested (mean increases 30 minutes post-dosing of 2.2 to 4.4 mmol/L [39-80 mg/dL] from euglycaemia and 1.3 to 5.2 mmol/L [24-94 mg/dL] from hypoglycaemia)
    2 context sentences
    Summary · context
    In this randomized double-blind trial, 17 patients received four single subcutaneous doses (0.03, 0.08, 0.2 and 0.6 mg) of dasiglucagon (4 mg/mL formulation) under euglycaemic (plasma glucose [PG] 5.6 mmol/L [100 mg/dL]) or hypoglycaemic (PG 3.1-3.7 mmol/L [56-66 mg/dL]) conditions.
    Summary · context
    For comparison, three doses (0.03, 0.08 and 0.2 mg) of a commercial glucagon formulation (Eli Lilly) were investigated at euglycaemia.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In type 1 diabetes, dasiglucagon led to dose-dependent mean glucose increases of 1.3 to 5.2 mmol/L (24-94 mg/dL) at 30 minutes post-dosing from hypoglycaemia.

    In plain wordsDasiglucagon increased glucose from low starting levels in adults with type 1 diabetes.

    Peptide
    Dasiglucagon
    Outcome
    IncreaseGlucose increase from hypoglycemia
    Study

    n = 17

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.03-0.6 mg · subcutaneousAs given in this study (human).

    Measurements

    Mean PG increase 30 min post-dosing, hypoglycaemia
    1.3 to 5.2 mmol/L
    dasiglucagon, range across doses tested
    Mean PG increase 30 min post-dosing, hypoglycaemia
    24 to 94 mg/dL
    dasiglucagon, range across doses tested

    Source sentences

    Summary
    Dasiglucagon led to a dose-dependent and rapid increase in PG levels across all doses tested (mean increases 30 minutes post-dosing of 2.2 to 4.4 mmol/L [39-80 mg/dL] from euglycaemia and 1.3 to 5.2 mmol/L [24-94 mg/dL] from hypoglycaemia)
    2 context sentences
    Summary · context
    In this randomized double-blind trial, 17 patients received four single subcutaneous doses (0.03, 0.08, 0.2 and 0.6 mg) of dasiglucagon (4 mg/mL formulation) under euglycaemic (plasma glucose [PG] 5.6 mmol/L [100 mg/dL]) or hypoglycaemic (PG 3.1-3.7 mmol/L [56-66 mg/dL]) conditions.
    Summary · context
    For comparison, three doses (0.03, 0.08 and 0.2 mg) of a commercial glucagon formulation (Eli Lilly) were investigated at euglycaemia.
  3. 03HumanRandomized controlled trialEfficacy outcome

    At euglycaemia, dasiglucagon produced higher glucose rises than similar doses of commercial glucagon, which produced rises of 1.7-3.9 mmol/L (30-71 mg/dL).

    In plain wordsDasiglucagon raised glucose more than similar doses of commercial glucagon.

    Peptide
    Dasiglucagon
    Outcome
    IncreaseGlucose increase versus commercial glucagon
    Study

    n = 17

    Comparator
    Similar doses of commercial glucagon (Eli Lilly), at euglycaemia
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.03-0.2 mg · subcutaneousAs given in this study (human).

    Measurements

    PG rise, commercial glucagon
    1.7 to 3.9 mmol/L
    commercial glucagon, similar doses, euglycaemia
    PG rise, commercial glucagon
    30 to 71 mg/dL
    commercial glucagon, similar doses, euglycaemia

    Source sentences

    Summary
    which was higher than the rises elicited by similar doses of commercial glucagon (1.7-3.9 mmol/L [30-71 mg/dL]).
    2 context sentences
    Summary · context
    In this randomized double-blind trial, 17 patients received four single subcutaneous doses (0.03, 0.08, 0.2 and 0.6 mg) of dasiglucagon (4 mg/mL formulation) under euglycaemic (plasma glucose [PG] 5.6 mmol/L [100 mg/dL]) or hypoglycaemic (PG 3.1-3.7 mmol/L [56-66 mg/dL]) conditions.
    Summary · context
    For comparison, three doses (0.03, 0.08 and 0.2 mg) of a commercial glucagon formulation (Eli Lilly) were investigated at euglycaemia.
  4. 04HumanRandomized controlled trialEfficacy outcome

    Median times to glucose increase above 1.1 mmol/L ranged from 9 to 15 minutes with higher dasiglucagon doses versus 13-14 with commercial glucagon.

    In plain wordsHigher dasiglucagon doses raised glucose in 9 to 15 minutes, compared with 13-14 minutes for commercial glucagon.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableTime to glucose increase at higher doses
    Study

    n = 17

    Comparator
    Commercial glucagon
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Higher doses · subcutaneousAs given in this study (human).

    Measurements

    Median time to PG increase >1.1 mmol/L
    9 to 15 minutes
    dasiglucagon, doses above 0.03 mg
    Median time to PG increase >1.1 mmol/L
    13 to 14 minutes
    commercial glucagon

    Source sentences

    Summary
    The median time (range) to an increase in PG of >1.1 mmol/L (20 mg/dL) was <20 (18-19.5) minutes with 0.03 mg dasiglucagon and, with higher doses, the median times ranged from 9 to 15 minutes (commercial glucagon 13-14 minutes).
    2 context sentences
    Summary · context
    In this randomized double-blind trial, 17 patients received four single subcutaneous doses (0.03, 0.08, 0.2 and 0.6 mg) of dasiglucagon (4 mg/mL formulation) under euglycaemic (plasma glucose [PG] 5.6 mmol/L [100 mg/dL]) or hypoglycaemic (PG 3.1-3.7 mmol/L [56-66 mg/dL]) conditions.
    Summary · context
    For comparison, three doses (0.03, 0.08 and 0.2 mg) of a commercial glucagon formulation (Eli Lilly) were investigated at euglycaemia.
  5. 05HumanRandomized controlled trialSafety outcome

    Nausea occurred more frequently with dasiglucagon than identical doses of commercial glucagon in type 1 diabetes.

    In plain wordsNausea occurred more often with dasiglucagon than with identical doses of commercial glucagon.

    Peptide
    Dasiglucagon
    Outcome
    IncreaseNausea
    Study

    n = 17

    Comparator
    Commercial glucagon at identical doses
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.03, 0.08 and 0.2 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Nausea and vomiting occurred more frequently with dasiglucagon than with commercial glucagon at identical doses which might be attributable to dasiglucagon's higher potency.
    2 context sentences
    Summary · context
    In this randomized double-blind trial, 17 patients received four single subcutaneous doses (0.03, 0.08, 0.2 and 0.6 mg) of dasiglucagon (4 mg/mL formulation) under euglycaemic (plasma glucose [PG] 5.6 mmol/L [100 mg/dL]) or hypoglycaemic (PG 3.1-3.7 mmol/L [56-66 mg/dL]) conditions.
    Summary · context
    For comparison, three doses (0.03, 0.08 and 0.2 mg) of a commercial glucagon formulation (Eli Lilly) were investigated at euglycaemia.
  6. 06HumanRandomized controlled trialSafety outcome

    Vomiting occurred more frequently with dasiglucagon than identical doses of commercial glucagon in type 1 diabetes.

    In plain wordsVomiting occurred more often with dasiglucagon than with identical doses of commercial glucagon.

    Peptide
    Dasiglucagon
    Outcome
    IncreaseVomiting
    Study

    n = 17

    Comparator
    Commercial glucagon at identical doses
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.03, 0.08 and 0.2 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Nausea and vomiting occurred more frequently with dasiglucagon than with commercial glucagon at identical doses which might be attributable to dasiglucagon's higher potency.
    2 context sentences
    Summary · context
    In this randomized double-blind trial, 17 patients received four single subcutaneous doses (0.03, 0.08, 0.2 and 0.6 mg) of dasiglucagon (4 mg/mL formulation) under euglycaemic (plasma glucose [PG] 5.6 mmol/L [100 mg/dL]) or hypoglycaemic (PG 3.1-3.7 mmol/L [56-66 mg/dL]) conditions.
    Summary · context
    For comparison, three doses (0.03, 0.08 and 0.2 mg) of a commercial glucagon formulation (Eli Lilly) were investigated at euglycaemia.
  7. 07HumanNon-randomized trialEfficacy outcome

    Median time to glucose increase above 1.1 mmol/L was <20 minutes (range 18-19.5) with dasiglucagon in type 1 diabetes.

    In plain wordsLow-dose dasiglucagon raised glucose within a median time below 20 minutes.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableTime to glucose increase at low dose
    Study

    n = 17

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.03 mg · subcutaneousAs given in this study (human).

    Measurements

    Median time to PG increase >1.1 mmol/L
    < 20 minutes
    0.03 mg dasiglucagon (median reported as <20)
    Range of time to PG increase >1.1 mmol/L
    18 to 19.5 minutes
    0.03 mg dasiglucagon

    Source sentences

    Summary
    The median time (range) to an increase in PG of >1.1 mmol/L (20 mg/dL) was <20 (18-19.5) minutes with 0.03 mg dasiglucagon and, with higher doses, the median times ranged from 9 to 15 minutes (commercial glucagon 13-14 minutes).
    2 context sentences
    Summary · context
    In this randomized double-blind trial, 17 patients received four single subcutaneous doses (0.03, 0.08, 0.2 and 0.6 mg) of dasiglucagon (4 mg/mL formulation) under euglycaemic (plasma glucose [PG] 5.6 mmol/L [100 mg/dL]) or hypoglycaemic (PG 3.1-3.7 mmol/L [56-66 mg/dL]) conditions.
    Summary · context
    For comparison, three doses (0.03, 0.08 and 0.2 mg) of a commercial glucagon formulation (Eli Lilly) were investigated at euglycaemia.
  8. 08HumanNon-randomized trialEfficacy outcome

    In hypoglycemia, dasiglucagon restored glucose to ≥3.9 mmol/L within a median 14 minutes.

    In plain wordsDasiglucagon restored normal glucose within a median 14 minutes.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableTime to normoglycemia
    Study

    n = 17

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.03 mg · subcutaneousAs given in this study (human).

    Measurements

    Median time to normoglycaemia (PG ≥3.9 mmol/L)
    14 minutes
    0.03 mg dasiglucagon, hypoglycaemia

    Source sentences

    Summary
    In hypoglycaemia, 0.03 and 0.08 mg dasiglucagon re-established normoglycaemia (PG ≥3.9 mmol/L [70 mg/dL]) within median times of 14 and 10 minutes, respectively.
    2 context sentences
    Summary · context
    In this randomized double-blind trial, 17 patients received four single subcutaneous doses (0.03, 0.08, 0.2 and 0.6 mg) of dasiglucagon (4 mg/mL formulation) under euglycaemic (plasma glucose [PG] 5.6 mmol/L [100 mg/dL]) or hypoglycaemic (PG 3.1-3.7 mmol/L [56-66 mg/dL]) conditions.
    Summary · context
    For comparison, three doses (0.03, 0.08 and 0.2 mg) of a commercial glucagon formulation (Eli Lilly) were investigated at euglycaemia.
  9. 09HumanNon-randomized trialEfficacy outcome

    In hypoglycemia, dasiglucagon restored glucose to ≥3.9 mmol/L within a median 10 minutes.

    In plain wordsDasiglucagon restored normal glucose within a median 10 minutes.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableTime to normoglycemia
    Study

    n = 17

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.08 mg · subcutaneousAs given in this study (human).

    Measurements

    Median time to normoglycaemia (PG ≥3.9 mmol/L)
    10 minutes
    0.08 mg dasiglucagon, hypoglycaemia

    Source sentences

    Summary
    In hypoglycaemia, 0.03 and 0.08 mg dasiglucagon re-established normoglycaemia (PG ≥3.9 mmol/L [70 mg/dL]) within median times of 14 and 10 minutes, respectively.
    2 context sentences
    Summary · context
    In this randomized double-blind trial, 17 patients received four single subcutaneous doses (0.03, 0.08, 0.2 and 0.6 mg) of dasiglucagon (4 mg/mL formulation) under euglycaemic (plasma glucose [PG] 5.6 mmol/L [100 mg/dL]) or hypoglycaemic (PG 3.1-3.7 mmol/L [56-66 mg/dL]) conditions.
    Summary · context
    For comparison, three doses (0.03, 0.08 and 0.2 mg) of a commercial glucagon formulation (Eli Lilly) were investigated at euglycaemia.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.